Technical Analysis for CARA - Cara Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
16.13 | -5.28% | -0.90 |
CARA closed down 5.28 percent on Thursday, December 5, 2019, on 2.7 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical CARA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Volume Surge | Other | -5.28% | |
| Calm After Storm | Range Contraction | -5.28% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 12/01/2019
- Sector: Healthcare
- Industry: Biotechnology
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
Chemistry Health Biopharmaceutical Pain Clinical Trial Piperidines Amines Mesoblast
Chemistry Health Biopharmaceutical Pain Clinical Trial Piperidines Amines Mesoblast
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
See more CARA news...
| Indicator | Value |
|---|---|
| 52 Week High | 27.55 |
| 52 Week Low | 12.19 |
| Average Volume | 645,872 |
| 200-Day Moving Average | 20.70 |
| 50-Day Moving Average | 20.42 |
| 20-Day Moving Average | 21.96 |
| 10-Day Moving Average | 22.43 |
| Average True Range | 1.41 |
| ADX | 31.88 |
| +DI | 20.28 |
| -DI | 47.15 |
| Chandelier Exit (Long, 3 ATRs ) | 22.44 |
| Chandelier Exit (Short, 3 ATRs ) | 20.29 |
| Upper Bollinger Band | 27.54 |
| Lower Bollinger Band | 16.39 |
| Percent B (%b) | -0.02 |
| BandWidth | 50.76 |
| MACD Line | -0.29 |
| MACD Signal Line | 0.56 |
| MACD Histogram | -0.8451 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.62 | ||||
| Resistance 3 (R3) | 17.76 | 17.40 | 17.37 | ||
| Resistance 2 (R2) | 17.40 | 17.03 | 17.33 | 17.28 | |
| Resistance 1 (R1) | 16.77 | 16.79 | 16.59 | 16.63 | 17.20 |
| Pivot Point | 16.41 | 16.41 | 16.33 | 16.34 | 16.41 |
| Support 1 (S1) | 15.78 | 16.04 | 15.60 | 15.64 | 15.06 |
| Support 2 (S2) | 15.42 | 15.80 | 15.35 | 14.98 | |
| Support 3 (S3) | 14.79 | 15.42 | 14.89 | ||
| Support 4 (S4) | 14.65 |
